0000950170-23-031788.txt : 20230705 0000950170-23-031788.hdr.sgml : 20230705 20230705174350 ACCESSION NUMBER: 0000950170-23-031788 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230705 DATE AS OF CHANGE: 20230705 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Phillips Gary M. CENTRAL INDEX KEY: 0001197795 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 231070968 MAIL ADDRESS: STREET 1: 675 MCDONNELL BLVD. CITY: HAZELWOOD STATE: MO ZIP: 63042 FORMER NAME: FORMER CONFORMED NAME: PHILLIPS GARY M DATE OF NAME CHANGE: 20021010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 4 1 ownership.xml 4 X0407 4 2023-06-30 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001197795 Phillips Gary M. C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE LEXINGTON MA 02421 true false false false false Stock Option (Right to Buy) 8.39 2023-06-30 4 A false 21222 0.00 A 2033-06-29 Common Stock 21222 21222 D Stock Option (Right to Buy) 8.39 2023-06-30 4 A false 1829 0.00 A 2033-06-29 Common Stock 1829 1829 D Stock Option (Right to Buy) 8.39 2023-06-30 4 A false 1372 0.00 A 2033-06-29 Common Stock 1372 1372 D Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. /s/ Gary Phillips 2023-07-05